Patient and Caregiver Experience With the Hope and Prognostic Uncertainty of Immunotherapy: A Qualitative Study
Authors:
- Mary C. BoulangerMBMary C. Boulanger
- Ayo S. FaladeAFAyo S. Falade
- Kelly HsuKHKelly Hsu
- Robert K. SommerRSRobert K. Sommer
- Roshni SarathyRSRoshni Sarathy
- Ryan J. SullivanRSRyan J. Sullivan
- Lara TraegerLTLara Traeger
- Joseph A. GreerJGJoseph A. Greer
- Jennifer S. TemelJTJennifer S. Temel
- Laura A. PetrilloLPLaura A. Petrillo
Top Cited Papers
- 1 February 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (2) , 178-187
Abstract
PURPOSE: Immunotherapy has improved survival for patients with melanoma and non–small cell lung cancer (NSCLC). Yet, as responses vary widely, immunotherapy also introduces challenges in prognostic communication. In this study, we sought to explore how patients and caregivers learned about the goal of immunotherapy and their experience of living with uncertainty. MATERIALS AND METHODS: We conducted a qualitative study of patients with stage III or IV melanoma or stage IV NSCLC within 12 weeks of initiating or 12 months of discontinuing immunotherapy, and their caregivers. We conducted in-depth interviews with participants to explore how they learned about immunotherapy from oncology clinicians and how they experienced uncertainty. We used a framework approach to analyze interview transcripts and synthesized concepts into themes. RESULTS: Forty-two patients and 10 caregivers participated; median age was 67 years and most were male (68%), white (95%), married (61%), and had melanoma (62%). We identified four themes: (1) the oncology team shaped participants' hopeful expectations of immunotherapy, including as a potential cure among those with melanoma; (2) distress related to prognostic uncertainty particularly affected patients who experienced toxicity or progressive disease; (3) patients who did not have long-term responses experienced overwhelming disappointment; and (4) some patients and caregivers had conflicting preferences for prognostic information. Participants provided suggestions to improve education and underscored unmet psychosocial needs. CONCLUSION: Patients and caregivers held optimistic expectations of immunotherapy, which resulted in heightened disappointment among the subset with progression or toxicity. Clinicians should elicit information preferences of both patients and caregivers, as these may be disparate. Our results highlight the need to optimize prognostic communication and support for living with uncertainty among patients receiving immunotherapy.Keywords
This publication has 44 references indexed in Scilit:
- A new landscape in illness uncertainty: A systematic review and thematic synthesis of the experience of uncertainty in patients with advanced cancer receiving immunotherapy or targeted therapyPsycho-Oncology, 2023
- Prognostic communication about lung cancer in the precision oncology era: A multiple‐perspective qualitative studyCancer, 2022
- Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced CancerThe Oncologist, 2021
- Patient and caregiver agreement on prognosis estimates for older adults with advanced cancerCancer, 2020
- Patient expectations are better for immunotherapy than traditional chemotherapy for cancerJournal of Cancer Research and Clinical Oncology, 2020
- Patient and clinician experience of a serious illness conversation guide in oncology: A descriptive analysisCancer Medicine, 2020
- Saturation in qualitative research: exploring its conceptualization and operationalizationQuality & Quantity, 2017
- A Framework to Improve Surgeon Communication in High-Stakes Surgical DecisionsJAMA Surgery, 2017
- Factors Considered Important at the End of Life by Patients, Family, Physicians, and Other Care ProvidersJAMA, 2000
- Relationship Between Cancer Patients' Predictions of Prognosis and Their Treatment PreferencesJAMA, 1998